Evaluate’s latest analysis forecasts an $82 billion increase in major product revenues in 2025 – the largest annual growth ...

It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their U.S.

Shares of Merck & Co. Inc. MRK slid 1.81% to $88.05 Thursday, on what proved to be an all-around mixed trading session for ...

During health secretary nominee Robert F. Kennedy Jr.'s Jan. 29 Senate confirmation hearing, Sen. Elizabeth Warren, D-Mass., ...

Here are seven attractively valued dividend stocks investors can bet on for the long term, according to Bank of America ...

DJIA stocks to watch today. Market trends show gains in retail, tech, and energy. Get insights on Walmart, Apple, Amazon, and more!

NEW YORK, NY / ACCESS Newswire / February 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Merck & ...

Co., Inc. (NYSE: MRK) has initiated a pivotal Phase 3 clinical trial, waveLINE-010, to evaluate the efficacy of its investigational drug zilovertamab vedotin in treating patients with previously ...

Learn more about whether Biogen Inc. or Gilead Sciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Mass General Brigham researchers discovered a previously unknown mechanism that may drive tissue damage and a new target for drug discovery ...

The Micro Immune Response On chip (MIRO) allows tumours and their environment to be replicated in order to understand their response to immunotherapy-based treatments. The device, which has already ...

Financial writer advises caution on investing in Merck & Co., Inc. due to negative sentiment and potential price declines. Click for more on MRK Q4 earnings.